AbbVie announced that Health Canada has approved MAVIRET, the oral glecaprevir/pibrentasvir combination, for the treatment of both acute and chronic hepatitis C virus infection in adults and in pediatric patients aged three years and older who weigh at least 12 kg.
The approval makes MAVIRET the first and only eight‑week pan‑genotypic oral therapy available in Canada. By adding an acute indication and a pediatric age‑weight criterion, the drug now covers a broader patient population, including the 214,000 Canadians who live with hepatitis C and the previously underserved children who can benefit from a short‑duration, single‑tablet regimen.
From a commercial perspective, the expanded indication positions AbbVie to capture a larger share of the Canadian hepatitis C market and to accelerate revenue generation. The eight‑week course offers a competitive advantage over longer‑duration therapies, potentially improving adherence and reducing treatment costs. The approval also aligns with the World Health Organization’s 2030 elimination goal, reinforcing AbbVie’s reputation as a leader in viral hepatitis treatment.
"Early detection and treatment of acute hepatitis C is critical to achieving the World Health Organization objective of eliminating HCV as a public health concern by 2030," said Dr. Brian Conway, Medical Director of the Vancouver Infectious Diseases Centre. Jennifer van Gennip, Executive Director of Action Hepatitis Canada, added that the approval “is a positive step that underscores the need for prevention and timely linkage to equitable care.”
The Canadian hepatitis C market remains highly competitive, with several oral therapies available. MAVIRET’s pan‑genotypic coverage and short duration differentiate it from other products that may target specific genotypes or require longer treatment courses. The pediatric formulation—coated granules in a sachet—addresses a critical unmet need, as few oral options exist for children under 12 kg.
In summary, Health Canada’s approval of MAVIRET expands AbbVie’s therapeutic reach, strengthens its competitive position, and supports global elimination efforts. The company’s ability to bring a first‑in‑class, eight‑week regimen to a broad patient base is expected to drive future growth in the hepatitis C segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.